Keryx Biopharmaceuticals Inc. (Nasdaq:KERX) announced that multiple abstracts for KRX-0401 (perifosine) have been selected for poster presentation at the upcoming 52nd Annual Meeting of the American Society of Hematology (NYSE:ASH), to be held in Orlando, Florida from December 4-7, 2010.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival.
Power3 Medical Announces Execution of Definitive Agreement to Acquire Rozetta-Cell Life Sciences
Power3 Medical Products, Inc. (OTC:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced recently that it has signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc.
Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger.
The acquisition of Rozetta-Cell is expected to be completed by end of Dec 2010.
Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. The company has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally.
Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors.
To learn more about PWRM visit: http://www.Power3Medical.com
Art Technology Group Inc. (Nasdaq:ARTG) the premier provider of cross-channel commerce solutions, announced that Brazilian sports retailer Netshoes has successfully completed the re-platform and re-launch of its web store using ATG Commerce as the foundation for a new, personalized site.
ATG (Nasdaq:ARTG) provides the most advanced cross-channel commerce software and services to fuel the growth of the world's best brands. Offering the industry's leading commerce solution, ATG works in partnership with clients to drive sales via a personalized customer experience - unifying and optimizing interactions across the Web, contact center, mobile devices, social media, physical stores, and other key channels.
Orofino Gold Corp. (ORFG.PK)
Orofino Gold Corp. is a US (Nevada) company established for the purpose of creating a significant exploration and mining group operating in Colombia.
The major criteria for selection of properties will include:
- Significant historical production
- Favorable geology for hosting major ore bodies
- Significant property area for large target exploration
- Recent results available
- Favorable infrastructure and access to allow mine development
- Receptive local government and populace.
- In addition Orofino has acquired a database comprised of exploration and mining results from previous operators who left when the global mining sector experienced a major downturn in the 1997-2000 time frame.
All properties meet the above criteria outlined above.
The second part of ORFG’s strategy to become a recognized player in the Colombia mining sector was the acquisition of an interest in an operating mine. ORFG has acquired a 55% interest in the La Azul/La Estrella property with the rights to acquire up to 80%.
To become a 100,000 ounce gold producer from first mine and to replicate this on each of the current optioned properties.
The vision of Orofino Gold Corp.:
- To become a good Joint Venture Partner
- To become a premier Mid Tier precious metals mining operation in Colombia
- To fast track first mine to commercial production.
Intrinsic, and essential, to this vision is ORFG’s moral, ethical and social commitment to develop the communities related to the projects.
To learn about ORFG visit: http://www.orofinogold.com
Sunesis Pharmaceuticals Inc. (Nasdaq:SNSS) announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 7,829,577, claiming the Company's pharmaceutical compositions of lead drug candidate vosaroxin. This patent is scheduled to expire on March 14, 2025, and could be eligible for patent term extension beyond this date. Corresponding patent applications are pending in major markets throughout the world including Europe, Japan, Australia and Canada.
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.
Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).
Crown Equity Holdings Inc. (OTCPK:CRWE) has received 500,000 shares of 144 stock in Orofino Gold Corp. (PINK SHEETS: ORFG) valued at sixty five thousand dollars, and 500,000 shares of free trading shares valued at sixty five thousand dollars from a third party (QU CUI You) for 30 days advertising.